Literature DB >> 28964959

Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing.

Kenko Azuma1, Tomohiro Umezu2, Satoshi Imanishi1, Michiyo Asano2, Seiichiro Yoshizawa2, Seiichiro Katagiri2, Kazuma Ohyashiki2, Junko H Ohyashiki3.   

Abstract

Bone marrow mesenchymal stromal cells (MSCs), which support proliferation and differentiation of hematopoietic stem cells, may play a crucial role in the pathogenesis of myeloid neoplasms. To determine whether MSCs in myeloid neoplasms harbor distinct somatic mutations that may affect their function, we used a targeted gene sequencing panel containing 50 myeloid neoplasm-associated genes with coverage of ≥500. We compared the genetic alterations between MSCs and bone marrow hematopoietic (BM) cells from patients with acute leukemia (n=5) or myelodysplastic syndrome (MDS, n=5). Non-synonymous somatic mutations, such as DNMT3A-R882H and FLT3-D835Y, were only detected in BM cells with high allelic frequency. We found several non-synonymous genetic variants overlapping BM cells and MSCs, including TP53 and ASXL1, partially owing to the heterogenous cell fraction of MSC samples and lineage fidelity. We also found MSC-specific genetic variants with very low allelic frequency (7% to 8%), such as NF1-G2114D and NF1-G140. Further studies in large cohorts are needed to clarify the molecular properties of MSCs including age-related genetic alterations by targeted deep sequencing.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone marrow mesenchymal stromal cells; Genetic variants; Myeloid malignancies; Targeted deep sequencing

Mesh:

Year:  2017        PMID: 28964959     DOI: 10.1016/j.leukres.2017.09.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma.

Authors:  Seiichiro Katagiri; Hideki Makishima; Kenko Azuma; Yasuhito Nannya; Yuu Saitoh; Seiichiro Yoshizawa; Daigo Akahane; Hiroaki Fujimoto; Yoshikazu Ito; Ravi Velaga; Tomohiro Umezu; Junko H Ohyashiki; Seishi Ogawa; Kazuma Ohyashiki
Journal:  Haematologica       Date:  2019-11-07       Impact factor: 9.941

2.  Downregulation of extracellular vesicle microRNA-101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression.

Authors:  Yuu Saitoh; Tomohiro Umezu; Satoshi Imanishi; Michiyo Asano; Seiichiro Yoshizawa; Seiichiro Katagiri; Tamiko Suguro; Hiroaki Fujimoto; Daigo Akahane; Chiaki Kobayashi-Kawana; Junko H Ohyashiki; Kazuma Ohyashiki
Journal:  Oncol Lett       Date:  2020-01-09       Impact factor: 2.967

3.  miR-7977 inhibits the Hippo-YAP signaling pathway in bone marrow mesenchymal stromal cells.

Authors:  Masahiro Yoshida; Hiroto Horiguchi; Shohei Kikuchi; Satoshi Iyama; Hiroshi Ikeda; Akari Goto; Yutaka Kawano; Kazuyuki Murase; Kohichi Takada; Koji Miyanishi; Junji Kato; Masayoshi Kobune
Journal:  PLoS One       Date:  2019-03-05       Impact factor: 3.240

Review 4.  Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.

Authors:  Bruno Fattizzo; Juri A Giannotta; Wilma Barcellini
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.